MedTrace Logo

A Composite Assay for HER2-positive Early-stage Breast Cancer Management

NCT06762977 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2025-01-08

No results posted yet for this study

Summary

The goal of this observational study is to assess the prognostic value of a genomic classifier (S18) and its refined version (S\*) in women with early-stage HER2-positive breast cancer. The study aims to determine whether these tools can predict event-free (EFS) and disease-free survival (DFS) in patients treated with neoadjuvant and/or adjuvant trastuzumab-based therapies.

Conditions

  • Breast Cancer Early Stage Breast Cancer (Stage 1-3)
  • HER2

Sponsors & Collaborators

  • Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale

    collaborator NETWORK

  • Ospedale Di Summa-Perrino

    collaborator UNKNOWN

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

    lead OTHER

Principal Investigators

  • Serena Di Cosimo, MD, PhD · Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

  • Paolo Verderio, PhD · Fondazione IRCCS Istituto Nazionale dei Tumori di Milano

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-13
Primary Completion
2025-08-31
Completion
2026-08-31

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06762977 on ClinicalTrials.gov